PEKING, May 10, 2025 (GLOBE NEWSWIRE) — Eine Erdgaspipeline, die sich über 3.000 Kilometer in Russland und 5.111 Kilometer in China erstreckt, wurde im Dezember letzten Jahres in Betrieb genommen und versorgt [...] Read more »
CGTN: كيف تُحدث العلاقات المستقرة بين الصين وروسيا توازنًا في عالم مضطرب؟
بكين, May 10, 2025 (GLOBE NEWSWIRE) —
بدأ تشغيل خط أنابيب [...] Read more »
Publication relating to transparency notifications
Publication relative à des notifications de transparence
INFORMATION RÉGLEMENTÉE
Publication relative à des notifications de transparence
Read more »
Invitation à assister à l'assemblée générale annuelle et extraordinaire des actionnaires de la Société qui se tiendra le 11 juin 2025
INFORMATIONS RÉGLEMENTÉES
le 9 mai 2025, 7:00h CET / 1:00h ET
NYXOAH SA
(Euronext Brussels/Nasdaq: NYXH)
Rue Edouard Belin 12, 1435 [...] Read more »
Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 11, 2025
REGULATED INFORMATION
May 9, 2025, 7:00am CET / 1:00am ET
NYXOAH SA
(Euronext Brussels: NYXH)
Rue Edouard Belin 12, 1435 Mont–Saint–Guibert, [...] Read more »
CGTN：How do stable China-Russia ties contribute to a turbulent world?
BEIJING, May 08, 2025 (GLOBE NEWSWIRE) — A natural gas pipeline that stretches 3,000 kilometers in Russia and 5,111 km in China commenced operations in December last year, benefiting about 450 million people along its [...] Read more »
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
Mont–Saint–Guibert, Belgium – [...] Read more »
Nyxoah Publiera ses Résultats Financiers du Premier Trimestre 2025 le 14 Mai 2025
Nyxoah Publiera ses Résultats Financiers du Premier Trimestre 2025 le 14 Mai 2025
Mont–Saint–Guibert, Belgique – 7 mai 2025, 22h30 [...] Read more »
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
Freiburg, May 7th, 2025
Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat [...] Read more »